“Fibroblast Activation Protein (FAP or Seprase) Inhibitor– Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Fibroblast Activation Protein (FAP or Seprase) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage
Fibroblast Activation Protein (FAP or Seprase) Inhibitor Understanding
Fibroblast Activation Protein (FAP or Seprase) Inhibitor: Overview
Fibroblast activation protein (FAP) is a serine protease that is generally accepted to play an important role in tumor growth and other diseases involving tissue remodeling. Currently there are no FAP inhibitors with reported selectivity toward both the closely related dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP). FAP expression is seen on activated stromal fibroblasts and pericytes of 90% of common human epithelial tumors examined. It has been established that FAP expression promotes tumorigenesis in mouse models and that FAP inhibition can attenuate tumor growth. FAP is also highly expressed in lesions characterized by activated stromal tissue such as present in cirrhosis, fibrotic diseases, osteoarthritis and rheumatoid arthritis, keloidosis, and in healing wounds. With FAP-affinities spanning almost 3 orders of magnitude, evaluation results of compounds 35–39 nonetheless reveal a pivotal importance of the nitrogen’s position. Of all the positional isomers synthesized, the 4-quinolinoyl ring of ’lead’ 7 clearly displays the best results and takes in a singular position within this series.
Fibroblast Activation Protein (FAP or Seprase) Inhibitor Emerging Drugs Chapters
This segment of the Fibroblast Activation Protein (FAP or Seprase) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fibroblast Activation Protein (FAP or Seprase) Inhibitor Emerging Drugs
• Talabostat - BioXcel Therapeutics
Talabostat is a small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines.
Further product details are provided in the report??..
Fibroblast Activation Protein (FAP or Seprase) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Fibroblast Activation Protein (FAP or Seprase) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Fibroblast Activation Protein (FAP or Seprase) Inhibitor
There are approx. 10+ key companies which are developing the Fibroblast Activation Protein (FAP or Seprase) Inhibitor. The companies which have their Fibroblast Activation Protein (FAP or Seprase) Inhibitor drug candidates in the most advanced stage, i.e. phase II include, BioXcel Therapeutics.
• Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Fibroblast Activation Protein (FAP or Seprase) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type


Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fibroblast Activation Protein (FAP or Seprase) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibroblast Activation Protein (FAP or Seprase) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibroblast Activation Protein (FAP or Seprase) Inhibitor drugs.


Report Highlights


  • • The companies and academics are working to assess challenges and seek opportunities that could influence Fibroblast Activation Protein (FAP or Seprase) Inhibitor R&D. The therapies under development are focused on novel approaches for Fibroblast Activation Protein (FAP or Seprase) Inhibitor.
    Fibroblast Activation Protein (FAP or Seprase) Inhibitor Report Insights
    • Fibroblast Activation Protein (FAP or Seprase) Inhibitor Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs
    Fibroblast Activation Protein (FAP or Seprase) Inhibitor Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Scenario and Emerging Therapies:
    • How many companies are developing Fibroblast Activation Protein (FAP or Seprase) Inhibitor drugs?
    • How many Fibroblast Activation Protein (FAP or Seprase) Inhibitor drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for Fibroblast Activation Protein (FAP or Seprase) Inhibitor?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fibroblast Activation Protein (FAP or Seprase) Inhibitor therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Fibroblast Activation Protein (FAP or Seprase) Inhibitor and their status?
    • What are the key designations that have been granted to the emerging drugs?
    Key Players
    • BioXcel Therapeutics
    • Roche
    • Riptide Bioscience
    • PsiOxus Therapeutics
    Key Products
    • Talabostat
    • Simlukafusp alfa
    • RP 832c
    • NG 600